Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
$31.92
-$0.14(-0.65%)
At close: 4:00 PM EST
$31.92
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$17.24 - $33.65
Previous CloseN/A
Volume229.76K
Average Volume (3M)2.13M
Market Cap
$19.65B
Enterprise Value$15.77B
Total Cash (Recent Filing)$3.41B
Total Debt (Recent Filing)$142.00M
Price to Earnings (P/E)13.4
Beta0.40
Next Earnings
Feb 05, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding642,384,100
10 Day Avg. Volume1,267,442
30 Day Avg. Volume2,131,656
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.65
Price to Sales (P/S)4.51
P/FCF Ratio12.81
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.12
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda2.64
Forecast
1Y Price Target
$41.00Price Target Upside28.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsSignificant recent clinical developments across Genmab's portfolio were highlighted, supporting an analyst's Buy recommendation.
Financial PerformanceGenmab's 3Q25 financial results showed a substantial earnings beat, highlighting strong financial performance.
Regulatory ApprovalsThe FDA approved Epkinly plus rituximab for the treatment of follicular lymphoma in the second-line-plus setting ahead of the original target date.
Bears Say
Market CompetitionInvestors and physicians struggle to prognosticate how the treatment landscape will emerge over the next several years due to similar response rates from competitors.
Risks And ChallengesRisks include slowing DARZALEX sales, failure to obtain DARZALEX label extensions, and negative readouts from DARZALEX trials.
Sales PerformanceEpkinly sales in the third quarter came below estimate, although no specific dynamics were attributed to this.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $33.65 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $19.65B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 05, 2026 which is in 69 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 10, 2025. The company reported $0.646 earnings per share for the quarter, beating the consensus estimate of $0.486 by $0.16.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.43.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 642,384,100 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.646 in its last earnings report, beating expectations of $0.486. Following the earnings report the stock price went up 1.396%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.00 (28.45% Upside)
$41.00 (28.45% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 15.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.57%
12-Months-Change
Fundamentals
Return on Equity
28.20%
Trailing 12-Months
Asset Growth
18.25%
Trailing 12-Months
Company Description
Genmab A/S
Genmab (GMAB) is a global biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on creating innovative treatments that leverage its proprietary antibody technology platform. The company has engaged in multiple partnerships with pharmaceutical firms to enhance its research and development capabilities, resulting in a robust pipeline of product candidates, including both fully owned and partnered assets.
GMAB Company Deck
GMAB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, a solid financial position, and strategic advancements with the proposed acquisition of Merus. However, there were some challenges, including the termination of GEN1042 development in head and neck cancer and a sales miss for EPKINLY. Overall, the positives of strong financial performance and strategic growth initiatives outweigh the negatives.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$41.00
▲(28.45% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.24% Mutual Funds
0.53% Other Institutional Investors
98.41% Public Companies and Individual Investors